Literature DB >> 16227613

Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform.

Adrianne Wong1, Silvia Bogni, Pille Kotka, Esther de Graaff, Vivette D'Agati, Frank Costantini, Vassilis Pachnis.   

Abstract

The receptor tyrosine kinase Ret plays a critical role in the development of the mammalian excretory and enteric nervous systems. Differential splicing of the primary Ret transcript results in the generation of two main isoforms, Ret9 and Ret51, whose C-terminal amino acid tails diverge after tyrosine (Y) 1062. Monoisoformic mice expressing only Ret9 develop normally and are healthy and fertile. In contrast, animals expressing only Ret51 have aganglionosis of the distal gut and hypoplastic kidneys. By generating monoisoformic mice in which Y1062 of Ret9 has been mutated to phenylalanine, we demonstrate that this amino acid has a critical role in Ret9 signaling that is necessary for the development of the kidneys and the enteric nervous system. These findings argue that the distinct activities of Ret9 and Ret51 result from the differential regulation of Y1062 by C-terminal flanking sequences. However, a mutation which places Y1062 of Ret51 in a Ret9 context improves only marginally the ability of Ret51 to support renal and enteric nervous system development. Finally, monoisoformic mice expressing a variant of Ret9 in which a C-terminal PDZ-binding motif was mutated develop normally and are healthy. Our studies identify Y1062 as a critical regulator of Ret9 signaling and suggest that Ret51-specific motifs are likely to inhibit the activity of this isoform.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227613      PMCID: PMC1265823          DOI: 10.1128/MCB.25.21.9661-9673.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2.

Authors:  M J Lorenzo; G D Gish; C Houghton; T J Stonehouse; T Pawson; B A Ponder; D P Smith
Journal:  Oncogene       Date:  1997-02-20       Impact factor: 9.867

2.  Identification of Shc docking site on Ret tyrosine kinase.

Authors:  E Arighi; L Alberti; F Torriti; S Ghizzoni; M G Rizzetti; G Pelicci; B Pasini; I Bongarzone; C Piutti; M A Pierotti; M G Borrello
Journal:  Oncogene       Date:  1997-02-20       Impact factor: 9.867

3.  Shc and Enigma are both required for mitogenic signaling by Ret/ptc2.

Authors:  K Durick; G N Gill; S S Taylor
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

Review 4.  The MEN II syndromes and the role of the ret proto-oncogene.

Authors:  B A Ponder; D Smith
Journal:  Adv Cancer Res       Date:  1996       Impact factor: 6.242

5.  Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.

Authors:  M Ohiwa; H Murakami; T Iwashita; N Asai; Y Iwata; T Imai; H Funahashi; H Takagi; M Takahashi
Journal:  Biochem Biophys Res Commun       Date:  1997-08-28       Impact factor: 3.575

6.  A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.

Authors:  N Asai; H Murakami; T Iwashita; M Takahashi
Journal:  J Biol Chem       Date:  1996-07-26       Impact factor: 5.157

7.  Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain.

Authors:  K Durick; R Y Wu; G N Gill; S S Taylor
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

Review 8.  The tip-top branching ureter.

Authors:  H Sariola; K Sainio
Journal:  Curr Opin Cell Biol       Date:  1997-12       Impact factor: 8.382

Review 9.  Signal transduction by the receptor tyrosine kinase Ret.

Authors:  D H van Weering; J L Bos
Journal:  Recent Results Cancer Res       Date:  1998

10.  GFR alpha1-deficient mice have deficits in the enteric nervous system and kidneys.

Authors:  H Enomoto; T Araki; A Jackman; R O Heuckeroth; W D Snider; E M Johnson; J Milbrandt
Journal:  Neuron       Date:  1998-08       Impact factor: 17.173

View more
  44 in total

1.  The many faces of RET dysfunction in kidney.

Authors:  Sanjay Jain
Journal:  Organogenesis       Date:  2009-10       Impact factor: 2.500

2.  Expression profiling the developing mammalian enteric nervous system identifies marker and candidate Hirschsprung disease genes.

Authors:  Tiffany A Heanue; Vassilis Pachnis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

Review 3.  To bud or not to bud: the RET perspective in CAKUT.

Authors:  T Keefe Davis; Masato Hoshi; Sanjay Jain
Journal:  Pediatr Nephrol       Date:  2014-04       Impact factor: 3.714

Review 4.  The genetics and epigenetics of kidney development.

Authors:  Sanjeevkumar R Patel; Gregory R Dressler
Journal:  Semin Nephrol       Date:  2013-07       Impact factor: 5.299

Review 5.  Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET.

Authors:  S W Moore; M G Zaahl
Journal:  Pediatr Surg Int       Date:  2008-03-26       Impact factor: 1.827

Review 6.  Advances in early kidney specification, development and patterning.

Authors:  Gregory R Dressler
Journal:  Development       Date:  2009-12       Impact factor: 6.868

Review 7.  Receptor tyrosine kinase signaling: regulating neural crest development one phosphate at a time.

Authors:  Katherine A Fantauzzo; Philippe Soriano
Journal:  Curr Top Dev Biol       Date:  2015-01-20       Impact factor: 4.897

8.  Branching morphogenesis.

Authors:  Arie Horowitz; Michael Simons
Journal:  Circ Res       Date:  2009-01-30       Impact factor: 17.367

9.  Angiotensin II-induced activation of c-Ret signaling is critical in ureteric bud branching morphogenesis.

Authors:  Renfang Song; Melissa Spera; Colleen Garrett; Ihor V Yosypiv
Journal:  Mech Dev       Date:  2009-12-02       Impact factor: 1.882

10.  Loss of Sprouty1 rescues renal agenesis caused by Ret mutation.

Authors:  Esteban J Rozen; Hagen Schmidt; Xavier Dolcet; M Albert Basson; Sanjay Jain; Mario Encinas
Journal:  J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.